| Literature DB >> 34207408 |
Romain Eychenne1,2, Michel Chérel2, Férid Haddad1,3, François Guérard2, Jean-François Gestin2.
Abstract
Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.Entities:
Keywords: actinium-225; astatine-211; bismuth-212; bismuth-213; lead-212; radium-223; targeted alpha therapy; terbium-149; thorium-227; α-emitters
Year: 2021 PMID: 34207408 PMCID: PMC8234975 DOI: 10.3390/pharmaceutics13060906
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321